Ustekinumab

This study suggests a relationship between higher ustekinumab trough concentrations and clinical remission in adults with Crohn’s disease, which could be relevant to patients and clinicians considering drug-level...

Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...

Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...

Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...

Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...

The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...

This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...

Knowing ustekinumab levels and anti-drug antibody status may help predict which people with Crohn’s disease are more likely to be in clinical remission and guide treatment adjustments.

Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.

The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...

A rapidly growing abdominal mass or unexplained systemic decline in someone with Crohn's disease may represent a rare malignancy (plasmablastic neoplasm) rather than infection or a disease flare; prompt biopsy is...

Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...

Patients and clinicians choosing among advanced therapies for ulcerative colitis may consider infection-related hospitalization risk as one factor; this study suggests lower risk with ustekinumab versus TNF antagonists...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from The American journal of gastroenterology.

Launches of adalimumab and ustekinumab could expand local access to two widely used biologic treatments for Crohn’s disease and ulcerative colitis. Wider availability may affect treatment options and logistics for people...

For people with Crohn’s disease, this study suggests that biologic drugs reduce inflammation in both proximal and distal small bowel to a similar degree, as measured by capsule endoscopy.

Patients and clinicians choosing a next biologic after prior biologic failure may find evidence here that effectiveness is broadly similar between vedolizumab and ustekinumab overall, with potential differences depending...

People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.

The study suggests adding a structured 16-week exclusive enteral nutrition plan to ustekinumab treatment may improve short- and medium-term clinical and endoscopic outcomes for adults with moderate-to-severe Crohn’s...

Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...

A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.

This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...

This report describes combined use of upadacitinib and ustekinumab to treat severe, refractory perianal Crohn’s disease in an adolescent — a scenario many patients and caregivers find especially difficult to manage.

Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Infliximab, and Ustekinumab.

Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...

If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.

People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...

This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase...

The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...

Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...

Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar...

Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...

Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which...

Based on the title and source metadata, this appears to be a clinical study related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from idp.nature.com.

Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...

The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when...

Patients and clinicians using ustekinumab may be able to use an early (around 3 months) drug concentration to help predict short-term remission, while routine repeated monitoring later on may be less informative for...

The findings give clinicians and patients data on how often biologic therapy leads to endoscopic remission in biologic‑naïve patients with isolated small‑bowel Crohn's disease, and they suggest similar effectiveness...

This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...

Postoperative endoscopic recurrence is common after ileocolonic resection for Crohn’s disease; this study suggests biologic drugs started after surgery are linked to lower recurrence rates. Knowing which biologics...

Head-to-head comparisons between biologics are uncommon but useful for patients and clinicians deciding between agents. This study specifically compares ustekinumab and infliximab for remission, safety, and quality of...

Chronic antibiotic-refractory pouchitis is a common, impactful complication after ileal pouch-anal anastomosis that can worsen quality of life and increase the risk of pouch failure. Patients and clinicians need clearer...

If validated, a genetic marker (IL12B rs6887695) might help predict which patients are more likely to benefit from ustekinumab, potentially informing personalized treatment choices in IBD.

Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

If pre‑treatment biopsy features predict response to ustekinumab, clinicians might better select which UC patients are likely to benefit, potentially avoiding ineffective therapy for some and speeding effective treatment...

People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...

This study provides real‑world data on how long biologic‑experienced UC patients stay on ustekinumab, which helps patients and clinicians set expectations about drug persistence and factors that might influence stopping...